

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number

WO 2022/040239 A8

(43) International Publication Date
24 February 2022 (24.02.2022)

WIPO | PCT

(51) International Patent Classification:

C07K 14/47 (2006.01) C12N 15/864 (2006.01)
A61K 48/00 (2006.01)

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2021/046382

(22) International Filing Date:

17 August 2021 (17.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/066,570 17 August 2020 (17.08.2020) US

(71) Applicant: MASSACHUSETTS INSTITUTE OF
TECHNOLOGY [US/US]; 77 Massachusetts Avenue,
Cambridge, MA 02139 (US).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(72) Inventors: FENG, Guoping; C/o The Broad Institute, Inc.,
415 Main Street, Cambridge, MA 02142 (US). GAO, Xian;
c/o The Broad Institute, Inc., 415 Main Street, Cambridge,
MA 02142 (US). MEI, Yuan; C/o The Broad Institute, Inc.,
415 Main Street, Cambridge, MA 02142 (US).

(48) Date of publication of this corrected version:

23 June 2022 (23.06.2022)

(74) Agent: TAN, Shirley et al.; Wolf, Greenfield & Sacks,
P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(15) Information about Correction:

see Notice of 23 June 2022 (23.06.2022)

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,

(54) Title: SHANK3 GENE THERAPY APPROACHES




FIG. 1B

(57) Abstract: Aspects of the disclosure relate to non-naturally occurring polynucleotides encoding a Shank3 protein, AAV vectors comprising the polynucleotides, and gene therapy methods.